Literature DB >> 3513562

Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review.

C E Freter, T C Lee, M E Billingham, L Chak, M R Bristow.   

Abstract

This report describes a patient treated for lymphoma who had development of doxorubicin (Adriamycin) cardiotoxicity proved by endomyocardial biopsy seven years after treatment. Doxorubicin cardiotoxicity is reviewed with emphasis on the implications of the long latency period for anthracycline cardiotoxicity in patients treated with this widely used antineoplastic agent.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3513562     DOI： 10.1016/0002-9343(86)90724-2

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


  10 in total

1.  Ventricular repolarization time indexes following anthracycline treatment.

Authors:  B Sarubbi; M Orditura; V Ducceschi; F De Vita; L Santangelo; F Ciaramella; G Catalano; A Iacono
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

Review 2.  [Genetics of dilated cardiomyopathy].

Authors:  L Thierfelder
Journal:  Med Klin (Munich)       Date:  1998-04-15

Review 3.  Anthracyclines and the heart.

Authors:  W Rhoden; P Hasleton; N Brooks
Journal:  Br Heart J       Date:  1993-12

4.  Biochemical changes induced by intravitreally-injected doxorubicin in the iris-ciliary body and lens of the rabbit eye.

Authors:  A C Phylactos; W G Unger
Journal:  Doc Ophthalmol       Date:  1998       Impact factor: 2.379

5.  Doxorubicin-induced cardiomyopathy 17 years after chemotherapy.

Authors:  Simi Kumar; Ravi Marfatia; Susan Tannenbaum; Clifford Yang; Erick Avelar
Journal:  Tex Heart Inst J       Date:  2012

6.  The Mechanism of Dynamic Interaction between Doxorubicin and Calf Thymus DNA at the Single-Molecule Level Based on Confocal Raman Spectroscopy.

Authors:  Ruihong Zhang; Jie Zhu; Dan Sun; Jie Li; Lina Yao; Shuangshuang Meng; Yan Li; Yang Dang; Kaige Wang
Journal:  Micromachines (Basel)       Date:  2022-06-13       Impact factor: 3.523

7.  Late effects of anthracycline therapy in childhood in relation to the function of the heart at rest and under physical stress.

Authors:  D Lang; F Hilger; J Binswanger; G Andelfinger; W Hartmann
Journal:  Eur J Pediatr       Date:  1995-05       Impact factor: 3.183

8.  Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model.

Authors:  D A Dodd; J B Atkinson; R D Olson; S Buck; B J Cusack; S Fleischer; R J Boucek
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

9.  Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.

Authors:  S Jelić; S Radulović; Z Nesković-Konstantinović; M Kreacić; Z Ristović; S Bosnjak; N Milanović; L Vuletić
Journal:  Support Care Cancer       Date:  1995-05       Impact factor: 3.603

10.  Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy.

Authors:  Paweł Stachowiak; Zdzisława Kornacewicz-Jach; Krzysztof Safranow
Journal:  Arch Med Sci       Date:  2013-04-30       Impact factor: 3.318
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.